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Abstract 
A phosphatidylcholine-like phospholipid expressed in the outer leaflet of the cell membrane shortly after mitogenic 
activation of T-cells is described, based on the binding of monoclonal antibody 90.60.3. Expression of the 90.60.3 
phospholipid antigen in T-cells is activation-dependent. Once expressed, the 90.60.3 phospholipid is in direct physical 
association with the interleukin-2 (IL-2) binding domain of IL-2 receptor a subunits, but does not affect IL-2 binding. The 
association is specific, because the 90.60.3 phospholipid is not found in association with other domains of IL-2 receptor ~t 
subunits, or near IL-2 receptor 13 or ~, subunits. Culturing cytokine-dependent cell lines in the presence of monoclonal 
antibody 90.60.3 potentiates IL-2-dependent cell survival and proliferation in a dose-dependent manner. In contrast, IL-4- 
dependent responses are not potentiated. Taken together, the data suggest hat specific plasma membrane phospholipids 
expressed in the outer leaflet after T-cell activation associate with the IL-2 binding domain of IL-2 receptor a subunits (and 
perhaps other cytokine receptors), and may play a role in regulating receptor mobility or signal transduction. © 1998 
Elsevier Science B.V. All rights reserved. 
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I. Introduction 
Hormones and polypeptide growth factors affect 
proliferation, differentiation, and cell survival by 
binding to specific receptors. Ligand binding to the 
extracellular domain of a receptor causes conforma- 
tional changes, receptor dimerization/oligomeriza- 
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tion, and changes in lateral mobility (reviewed in 
[1]). These events are influenced in part by the lipid 
composition and the fluidity of the plasma mem- 
brane in which the receptors are embedded. 
The IL-2 receptor (IL-2R) is composed of distinct 
ligand binding components and associated signaling 
components [2-5]. IL-2 is a polypeptide growth fac- 
tor which regulates proliferation and differentiation 
of T-cells, B-cells, NK cells, and other cell types. 
Based on ligand binding, three distinct IL-2R have 
been described as low (Kd ~ 10 nM); intermediate 
(Kd '~ l  nM); and high affinity (Kd~10 pM) [6]. 
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Three distinct IL-2R cDNAs have been cloned [7] 
and termed IL-2R~, IL-2RI3 and IL-2Ry. The high 
affinity functional IL-2R consists at least of ~13y sub- 
units associated non-covalently as heterotrimers (re- 
viewed in [8]). 
IL-2R~ subunits bind IL-2 with low affinity when 
expressed in the absence of other subunits [9]. No 
intrinsic signal transduction has been associated to 
IL-2Ra subunits. However, IL-2R~ affects the signal 
transduced by the IL-2RI3y complex [10]. IL-2Ry 
subunits alone do not bind IL-2 with detectable af- 
finity [7]. However IL-2Ry subunits mediate signal 
transduction when non-covalently associated with 
IL-2Ra and IL-2R[3 subunits. The IL-2Ry subunit 
can also transduce signals for IL-4 and IL-7 by asso- 
ciating with their selective receptors [11-13]. IL-2RI3 
subunits do not bind IL-2 significantly [7,14] and do 
not transduce signals in the absence of other sub- 
units. However, IL-2RI3y heterodimers (in the ab- 
sence of IL-2R~) bind IL-2 with intermediate affinity 
(Kd "~ 1 nM), and mediate signal transduction [15]. 
Signal transduction via IL-2R is complex (re- 
viewed in [16-19]); and expression of the three IL- 
2R subunits does not necessarily correlate with IL-2 
responsiveness [20]. Functional evidence exists for 
IL-2R accessory or adapter molecules, such as 
PLCy and PI-3-kinase [21,22]; the src family of solu- 
ble kinases, and Shc, JAK, and STAT kinases 
[9,17,18,23,24]. However, these accessory signaling 
molecules may not be absolutely required [25]. Evi- 
dence exists for other putative IL-2R associated com- 
ponents that co-precipitate with or are physically 
linked with IL-2R subunits on the cell membrane 
[25 29]. However, these putative IL-2R-associated 
proteins have not been shown to play a role in signal 
transduction. 
The composition of the plasma membrane has 
been reported to influence receptor mobility and li- 
gand affinity. We therefore hypothesized that the lip- 
id composition of the activated T-cell may affect the 
signals of IL-2R or other cytokines. We report a 
phosphatidylcholine-like phospholipid antigen (rec- 
ognized by mAb 90.60.3) expressed on the outer leaf- 
let of the plasma membrane in activated T-cells. The 
90.60.3 phospholipid is in association with the IL-2- 
binding domain of IL-2R~ subunits without affecting 
IL-2 binding. In contrast, the 90.60.3 phospholipid is 
not physically associated with the IL-2R[3 or IL-2Ry 
subunits or with other surface T-cell antigens. The 
90.60.3 phospholipid is functionally linked to signal 
transduction i duced by IL-2 because culture with 
mAb 90.60.3 increases the effect of suboptimal IL- 
2. IL-3-dependent signals are also enhanced by cul- 
ture with mAb 90.60.3, but to a much lesser degree; 
and IL-4-dependent responses are not enhanced at 
all. This suggests that the 90.60.3 phospholipid is 
involved preferentially in the IL-2 signal cascade. 
Taken together, the data suggest that the phospho- 
lipid-like molecule defined by mAb 90.60.3 may rep- 
resent a membrane component which can associate 
physically with a specific subdomain of IL-2R~ sub- 
units, and functionally with high affÉnity IL-2R. Its 
potential association with other receptors is not ex- 
cluded. 
2. Materials and methods 
2.1. Hybridoma production 
Female Lewis rats were immunized subcutaneously 
and intraperitoneally with live CTL-L mouse T-cells 
grown in logarithmic phase. Splenocytes were fused 
with SP2/0 myeloma cells [30]. Hybridoma culture 
supernatant screening was done against HT-2 cells 
by indirect FACScan analysis with FITC-labeled 
goat anti-rat-antibody (Sigma, St. Louis, MO). Cells 
from wells scored positive were subcloned by limiting 
dilution, expanded in non-selecting media, and tested 
in proliferation assays described below. A stable sub- 
clone which bound a cell surface antigen of CTL-L 
and HT-2 cells, and affected IL-2 dependent prolif- 
eration was identified as rat mAb 90.60.3. 
2.2. Cells 
Cells used for analyzing expression of 90.60.3 anti- 
gen, IL-2R~, IL-2R[3, and IL-2Ry subunits are listed 
in Table 2A. Cytokine-dependent mouse cells were 
used for biological assays: IL-2-dependent (and IL-4 
responsive) CTL-L and HT-2 cells; IL-4-dependent 
CT4S cells which were derived from CTL-L [31]; and 
IL-3-dependent BAF-3 cells. Culture media (RPMI 
1640 supplemented with 2 mM glutamine, 1 mM 
sodium pyruvate, 10 mM HEPES, 0.1 mM non-es- 
sential amino acids, penicillin, streptomycin, and 5- 
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10% heat-inactivated FCS) was supplemented with 
lymphokines as indicated (either 50 U/ml IL-2 
(Boehringer Mannheim Biochemicals, Indianapolis, 
IN); 200 U/ml IL-4 (a gift of Dr. W. Paul, NIH); 
or 10% WEHI-3B conditioned media containing 
IL-3). 
Normal T-cells were isolated from thymus, spleen, 
or lymph nodes of mice (CBA/Ca (H-2k), C57BL/6 
(H-2 b) and BALB/c (H-2 d) (NIH, Betheseda, MD). 
Cells were analyzed irectly or after mitogenic stim- 
ulation with ConA; with anti-TCR Abs (anti-TCR[3 
mAb clone H57-597 [32], anti-CD3e mAb clone 
500A2 [33], and cross-linking with syngeneic T-de- 
pleted irradiated splenocytes); or with phorbol ester 
(PMA, 50 ng/ml) and Ca 2+ ionophore (ionomycin, 
1 Bg/ml)). 
2.3. Proliferation and survival assays 
Five thousand cells/well were added to serial dilu- 
tions of recombinant cytokine in 96-well plates (Co- 
star). The MTT assay modified as described [34] was 
used to quantitate proliferation and survival of cyto- 
kine-dependent cells (the MTT assay is a measure of 
both events). One unit/ml of IL-2 was arbitrarily 
defined as the concentration required to support 
the half-maximal growth of HT-2 cells over a 24- 
36 h incubation period. 
2.4. Antibodies, fluorescent labels, and f low cytometry 
Cultured or normal cells (5 × 105 cells/tube, > 95% 
viable) were suspended in FACS buffer (PBS, 1% 
BSA, 0.1% Na azide) and immunostained. After fur- 
ther washing, cells were analyzed on a FACScan 
(Becton Dickinson, Mountain View, CA). Immuno- 
staining for surface 90.60.3 antigen used either di- 
luted 90.60.3 ascitic fluid, followed by 0.5 Bg/tube 
of FITC-coupled goat (Fab')2 anti-rat Ig (Pierce, 
Rockford, IL); or mAb 90.60.3-biotin followed by 
with 0.5 Bg/tube of Red613-coupled avidin or 
FITC-coupled avidin (Gibco BRL). Biotinylation 
was performed with long arm biotin (Pierce) as per 
manufacturer's instructions. For two color staining 
(CD4 or CD8/90.60.3 or p55t~), primary labeling 
with mAb 90.60.3 (90.60.3-biotin plus Avidin- 
FITC) or anti-IL-2Ro~ mAb 7D4 (7D4-FITC) was 
followed with 50 Bg/tube rat Ig (Sigma, St. Louis, 
MO) for blocking; together with anti-CD4 PE (clone 
YTS, Gibco BRL, Gaithersburg, MD) or anti-CD8 
Red613 (clone 53-6.7, Gibco BRL). mAb 7D4-FITC 
was a gift of Dr. T.R. Malek (University of Miami). 
Other biotinylated antibodies used (e.g. to assess the 
purity of T-cells) included anti-all TCR (clone H57- 
597, PharMingen); anti-CD3-e (clone 145-2Cll, 
PharMingen); the anti-IL-2Rtx mAbs 7D4 (Phar- 
Mingen), AMT13, and 5A2 [35]; the anti-class I
MHC mAb M1.42; anti-IL-2R~ mAb TM~I and 
anti-IL-2R 7 mAb TUGm2 [20]. 
2.5. Blocking~competition assays 
HT-2 or CTL-L cell suspensions were first bound 
with saturating concentrations of anti-IL-2Rt~ mAbs 
7D4, 3C7, AMT-13, or 5A2; anti-IL-2RI] mAb 
TM[~I, anti-IL-2R 7 mAb TUGm2; anti-class I 
MHC mAb M1.42; with 50 btg/ml rat Ig; with IL-2 
(1000 U/ml); or with mAb 90.60.3. After washing, 
the binding of the same ligands (directly labeled or 
biotinylated) was tested by FACScan analysis as de- 
scribed above. Competition of IL-2 was assessed us- 
ing 125I[IL-2] in Scatchard plot analysis. 
2.6. EL ISA 
Test compounds for 90.60.3 binding assays were 
prepared at a concentration f 0.25 mg/ml and stored 
at -20°C. Soluble in methanol: 13-oleoyl-),-palmito- 
yl-phosphatidylcholine (POPC), phosphatidyletha- 
nolamine (PEA), diheptanoyl-e-tx-phosphatidylcho- 
line (DHPC), didecanoyl-L-o~-phosphatidylcholine 
(DDPC), and dilauroyl-e-~-phosphatidylcholine 
(DLPC) (Sigma, St. Louis, MO), sphingomyelin 
(SM) and sphingosine (Matreya, Pleasant Gap, 
PA); dioctanoyl-L-tx-phosphatidylcholine (DOPC), 
dimyristoyl-L-ot-phosphatidylcholine (DMPC), dipal- 
mitoyl-L-t~-phosphatidylcholine (DPPC), and dist- 
earoyl-L-o~-phosphatidylcholine (DSPC) (Avanti Po- 
lar Lipids, Alabaster, AL). Soluble in water: choline 
chloride (Sigma, St. Louis, MO) and dibutyroyl-L-tX- 
phosphatidylcholine (DBPC) (Avanti Polar Lipids, 
Alabaster, AL). Soluble in dimethylsulfoxide 
(DMSO): C2-ceramide (Sigma, St. Louis, MO; a 
gift from Dr. B. Collier (McGill University)). Solvent 
selection and solubility was strictly dependent on the 
length of the lipid tail. 
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Table 1 
Identification of the minimal antigenic epitope of mAb 90.60.3 
(A) Test antigen C-Lipid chain(s) % Binding ± S.E.M. 
1 POPC 16, 18 a 100.0 ± 0.0 
2 Phosphatidylethanolamine 16, 18 a 17.6 ± 2.2 
3 Choline Chloride no lipid -5.7 ± 1.9 
4 Sphingomyelin 18 a 7.6 ± 0.8 
5 Sphingosine 16 ~ -5.9 ± 3.3 
6 C2-Ceramide 16 ~ 0.4 ± 0.0 
7 DBPC 4, 4 2.4 ± 1.2 
8 DHPC 6, 6 -0.4+0.8 
9 DOPC 8, 8 1.4±0.7 
10 DDPC 10, 10 2.8+0.7 
11 DLPC 12, 12 16.5-+1.6 
12 DMPC 14, 14 13.3-+1.1 
13 DPPC 16, 16 8.1 +0.8 
14 DSPC 18, 18 14.2±1.5 
(B) Test antigen % Binding ± S.E.M. 
+PEA lipids +SM lipids 
1 Choline 32.9 ± 1.6 not tested 
2 Sphingomyelin 92.7 ± 7.4 not tested 
3 DBPC 26.8 ± 3.9 9.4±3.1 
4 DHPC 19.7 ± 0.5 1.2 ± 2.0 
5 DOPC 27.5±0.5 0.4+3.1 
6 DDPC 38.0 ± 1.8 1.8 ± 2.3 
7 DLPC 57.5 ± 3.3 27.7 ± 6.4 
8 DMPC 60.6± 1.5 49.4 ± 9.6 
9 DPPC 26.5 ± 0.4 46.9 ± 7.8 
10 DSPC 8.6± 1.1 30.1 ±0.9 
ELISAs were done with mAb 90.60.3 or control rat Ig. For detailed lipid structures ee Fig. 1. (A) Single test lipid. The indicated lip- 
ids were immobilized onto 96-well plates. The length of each carbon lipid chain(s) is shown. OD values from ELISAs are expressed as 
percent binding standardized to the binding of POPC (100%). Data from 4-20 independent experiments; n=4-8 wells/experiment; 
+ S.E.M. (B) Assembly of the epitope by combination of antigens. The indicated Ags were combined either with phosphatidylethanol- 
amine (+PEA lipid), or with sphingomyelin (+SM lipid). OD values from ELISAs were standardized to the binding of POPC in the 
same plates (100%). Data from 3-6 independent experiments; n = 8 wells/experiment; ±S.E.M. 
aC = C double bond in the lipid chain. 
The above compounds were further diluted in 
water (usually 1:25). Each compound (,-~0.66 
nmol; 50 B1/well final volume) was immobil ized by 
drying onto polystyrene 96-well plates (VWR-Can-  
lab, Ville Mont-Royal ,  Que.). Plates were blocked 
for 2 h at room temperature (blocking buffer (BB): 
PBS pH 7.4, 1% BSA). mAb 90.60.3 or control rat Ig 
(primary Abs) were diluted in BB to 24  ~tg/ml. mAb 
90.60.3 (test) and rat Ig (background control) were 
added to each well (~  100 ng/well) containing test 
compounds or no compounds (background control). 
After 1 h at room temperature, plates were washed 
three times with BB, followed by 1 h incubation with 
peroxidase-conjugated affinity-purified goat anti-rat 
Ig (H+L)  secondary antibody (~ 25 ng/well) (Sigma, 
St. Louis, MO). After washing three times with BB 
and three times with PBS, the peroxidase substrate 
ABTS (2,2'-azinobis(3-ethylbenzthiazoline-sulfonic 
acid)) (Sigma, St. Louis, MO) was added (freshly 
prepared (0.4 mg/ml) in 0.062 M citric acid, 0.076 
M NazHPO4, 5 Bl/ml 30% hydrogen peroxide). The 
enzymatic reaction was stopped by adding an equal 
volume of 2% oxalic acid after 5-15 min. Absorb- 
ance was measured at 414 nm in a microplate reader 
(Bio-Rad Laboratories, Mississauga, Ont.). Optical 
density (OD) values minus background control 
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were calculated. The OD of primary rat Ig or mAb 
90.60.3 without test antigen in the well were near 
zero. All values obtained with control rat Ig with 
test antigen in the well were near zero. 
3. Results 
3.1. Biochemical characterization of the 90.60.3 
antigen reveals aphospholipid 
Biochemical tests failed to consistently detect a 
polypeptide recognized by mAb 90.60.3 (data not 
shown). Thus, we hypothesized that the 90.60.3 anti- 
gen might be a cell surface phospholipid moiety (Fig. 
1). Several phospholipids were tested in ELISA for 
specific binding to mAb 90.60.3 (Table 1A). Combi- 
nations of two phospholipids were also tested by 
mixing them prior to ELISA (Table 1B). 
13-Oleoyl-7-palmitoyl-phosphatidylcholine (POPC) 
was the strongest binding phospholipid. POPC bind- 
ing by mAb 90.60.3 consistently produced values 
OD > 0.500; while POPC binding by control rat Ig 
produced values OD < 0.040. Thus, the absorbance 
of POPC was standardized to 100% to allow direct 
comparisons of all compounds (Table 1A, row 1). 
~i-Oleoyl-y-palmitoyl-phosphatidylethanolamine 
(PEA) is related to POPC, except hat ethanolamine 
(+NH3) substitutes the choline (+N(CH3)3) head of 
POPC (see Fig. 1). PEA had low binding to mAb 
90.60.3 (Table 1A, row 2), suggesting that the choline 
head of POPC is an important moiety. Choline had 
no specific binding to mAb 90.60.3 (Table 1A, row 
3), suggesting that the rest of POPC is also impor- 
tant. 
Sphingomyelin (SM) is a compound related to 
POPC, except that an hydroxyl group, a peptide 
bond, and a C = C double bond substitute two ester 
bonds and a ketone in POPC (see Fig. 1). SM had 
low but significant specific binding to mAb 90.60.3 
(Table 1A, row 4). This suggests either that the esters 
or the ketone in POPC may be important, or that the 
substitutants in SM interfere with mAb 90.60.3 bind- 
ing. Sphingosine and C2-ceramide had no specific 
binding to mAb 90.60.3 (Table 1A, rows 5 and 6), 
as expected because they have no choline head and a 
single lipid chain. 
To test the possible role of the length of the lipid 
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chain, we tested a variety of phospholipids (DBPC, 
DHPC, DOPC, DDPC, DLPC, DMPC, DPPC, 
DSPC). These lipids contain chains ranging in length 
from (;4 to C18 (Table 1A, rows 7-14); and mimic 
POPC in every respect except hat the lipid chains 
lack a C=C double bond (see Fig. 1). DBPC, 
DHPC, DOPC, and DDPC (C4-C10 lipid chain 
lengths) have no specific binding to mAb 90.60.3 
(Table 1A, rows 7-10), while DLPC, DMPC, 
DPPC, and DSPC (C12-C18 lipid chain lengths) 
have low, but significant, specific binding to mAb 
90.60.3 (Table 1A, rows 11-14). This suggests that 
the required lipid chain length is at least 12 carbons. 
The presence of the C = C double bond is also im- 
portant for binding mAb 90.60.3 
Taken together, these data indicate that the mini- 
mal antigen is comprised of three moieties: (1) cho- 
line; (2) a diester linkage; and (3) two lipid chains of 
12-18 carbons in length containing at least one C = C 
double bond. The C = C double bond may contribute 
to changes in geometry, flexibility, or a propensity to 
rotate or flip the lipid chain. 
3.2. The 90.60.3 phospholipid antigen can be 
assembled in vitro 
Next, we hypothesized that the three moieties that 
comprise the 90.60.3 antigen could be reconstituted 
in vitro by mixing the appropriate phospholipids. It 
was expected that each of the moieties could be ori- 
ented in a manner suitable for mAB 90.60.3 binding; 
or that induced fit by mAb 90.60.3 could force as- 
sembly. 
Different compounds were mixed and tested by 
ELISA for binding to mAb 90.60.3 (Table 1B). A 
combination of choline+PEA resulted in ,~ 33% of 
mAb 90.60.3 binding compared to POPC (Table 1B, 
row 1). This would be expected if addition of choline 
compensated for the chemical difference between 
PEA and POPC. Assembly is evident because PEA 
alone had low binding and choline alone had no 
specific binding to mAb 90.60.3 (Table 1A, rows 2 
and 3). A mixture of SM+PEA restores ,~ 93% of 
mAb 90.60.3 binding (Table IB, row 2). In contrast, 
mAb 90.60.3 binding to each SM or PEA was very 
low (8 and 18%, respectively, Table 1A, rows 2 and 
4). 
The series of phospholipids DBPC, DHPC, 
DOPC, DDPC, DLPC, DMPC, DPPC, and DSPC 
(C4-C18 in length) were also tested in combination 
with PEA or SM (Table 1B, rows 3-10). The most 
efficient combination is that of DMPC+PEA or 
DMPC+SM (Table 1B, row 8). DLPC+PEA also 
binds efficiently (Table 1B, row 7), as does 
DPPC+SM (Table 1B, row 9). 
Therefore, it seems that mAb 90.60.3 recognizes a 
phospholipid-like molecule similar to POPC; or a 
combination of phospholipid mixtures expressed in 
the plasma membrane. 
3.3. Characterization of the biological activity of mAb 
90.60.3 
The screening used to isolate hybridoma 90.60.3 
used conditioned media containing mAb 90.60.3. 
The conditioned media synergized with suboptimal 
concentrations of IL-2 in increasing IL-2-dependent 
HT-2 and CTL-L proliferation as assessed by 3H- 
thymidine incorporation assays and MTT colorimet- 
ric assays (data not shown). These assays were re- 
peated using purified mAb 90.60.3 to confirm that 
they were due to the mAb (Fig. 2). 
Serial dilutions of mAb 90.60.3 with constant 0.1 
U/ml IL-2 were tested in MTT assays (Fig. 2A). An 
estimated 1 nM (,~ 1 I.tg/ml) mAb 90.60.3 afforded 
optimal synergy with 0.1 U/ml IL-2. Control cultures 
with no antibody added (data not shown), or with 
equimolar concentrations of rat Ig (Fig. 2A) did not 
synergize with IL-2, and showed biological responses 
typical of simple IL-2 dilutions. 
A constant concentration of 1 nM (1 gg/ml) puri- 
fied mAb 90.60.3 was tested versus erial dilutions of 
IL-2 (Fig. 2B). Synergy was observed at suboptimal 
concentrations of IL-2 (ranging from 0.0054). 15 U/ 
ml), and resulted in increased HT-2 cell survival and 
proliferation to ,~ 50% of the maximum achieved 
with optimal IL-2 concentrations. The maximal re- 
sponse achieved at optimal IL-2 concentrations was 
not affected by mAb 90.60.3. Control assays with 
purified rat Ig added to cultures (Fig. 2B) did not 
synergize with IL-2; and yield profiles typical of sim- 
ple IL-2 dilutions. 
Similar tests were performed with the IL-3-depend- 
ent BAF-3 cell line. Some synergy between mAb 
90.60.3 and low concentrations of IL-3 (ranging 
from 0.005 to 0.15 U/ml) afforded increased cell sur- 
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Fig. 2. Biological synergy of mAb 90.60.3 and IL-2. Cells were 
cultured with the indicated ligands. After 24-36 h proliferation 
was assessed by the MTT method. Similar results were obtained 
with 3H-thymidine incorporation (not shown). (A) Response of 
HT-2 cells to dilutions of 90.60.3 mAb or rat Ig and constant 
0.1 U/ml IL-2. (B) Response of HT-2 cells to increasing doses 
of IL-2 and constant 1 pg/ml 90.60.3 mAb or rat Ig. 
vival and proliferation to ,-,20% of that achieved 
with optimal IL-3 concentrations (Fig. 3). Synergy 
was evident at suboptimal concentrations of IL-3, 
but the maximal response afforded by optimal IL-3 
concentrations was not increased. Addition of con- 
trol rat Ig had no effect in these assays. 
In contrast, mAb 90.60.3 did not potentiate the 
survival and proliferation of IL-4-dependent CT4S 
cells in response to IL-4. The dose response of 
CT4S cells to IL-4 was identical whether at Ig, 
mAb 90.60.3 or no rat Ig was added to the cultures 
(data not shown). Similarly, the survival and prolif- 
eration of CTL-L cells (IL-2 dependent, but are IL-4 
responsive) were not potentiated by mAb 90.60.3 at 
any dose of IL-4 (data not shown). 
3.4. IL-2R subunits and the 90.60.3 phospholipid are 
independently expressed 
Binding of mAb 90.60.3 to the outer leaflet of the 
plasma membrane was surveyed in a variety of 
mouse and human cell lines by flow cytometry. 
Moreover, given the synergy of mAb 90.60.3 with 
IL-2 we explored whether mAb 90.60.3 recognized 
any of the three IL-2R subunits (Table 2A). 
Flow cytometric analysis of intact cells revealed 
high levels of mAb 90.60.3 binding to the surface 
of the RI.1 thymoma cell line. RI.1 cells do not 
express IL-2Ro~ protein or mRNA, do not react 
with several anti-IL-2Rc~ mAbs (e.g. mAb 7D4 (Ta- 
ble 2A), 3C7, AMT-13, or 5A2 (data not shown)), 
and do not bind ]25I[IL-2] (data not shown). Thus, 
R I.1 cells do not express IL-2R~ subunits, but do 
express the 90.60.3 phospholipid. 
EL4 cells do not express urface 90.60.3 phospho- 
lipid or IL-2R~ subunits, but do express IL-2R~7. 
Expression of IL-2Ra subunits in EL4 cells (upon 
stable transfection ofmouse IL-2R~ eDNA) [28] per- 
mits binding of anti-IL-2Ro~ mAbs (mAbs 7D4, 3C7, 
AMT-13, and 5A2 (data not shown)). In contrast, 
.280- 
O control rat Ig = ,~-  
.260- • 90.60 .3  mAb 
O~ ~!' .240- 
,.4 
.220" 
.200 . . . . . . . . . .  
.oo~ .o~ .~ ~ ~o ~oo 
I L -3  UNITS /ml  
Fig. 3. Low synergy of mAb 90.60.3 and IL-3. Proliferation of 
BAF cells to increasing doses of IL-3 (WEHI cell conditioned 
supernatant) in the presence of mAb 90.60.3 or rat Ig control. 
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Table 2 
Phenotypic analysis of IL-2R subunits and 90.60.3 Ag 
(A) Cell lines 90.60.3 mAb + anti-IL-2R~ anti-IL-2RI3 anti-IL-2Ry 
HT-2 (IL-2 dependent mouse T-cell) 
CTL-L (IL-2 dependent mouse T-cell) 
CT4.S (IL-4 dependent mouse T-cell) 
BAF-3 (IL-3 dependent mouse pre-B-cell) 
RI.1 (mouse thymoma) 
EL4 (mouse thymoma) 
EL4J-3.4 (IL-2Rct transfected EL4) 
TS1 (IL-9 dependent mouse T-cell) 
high high low low 
high high low low 
intermediate low not tested low 
intermediate low negative low 
high negative low not tested 
negative negative low low 
negative high low low 
negative negative negative high 
(B) Mitogen 90.60.3 + 7D4 + anti-IL-2Rct 
CD4 + CD8 + CD4 + CD8 + 
ConA 
0 h 7 6.2 4 3.3 
9 h 3 4 28 21 
18 h 16 25 22 27 
27 h 35 29 46 42 
36 h 34 36 47 44 
cxTCR mAb 
0 h 8.3 5.2 4.8 1.69 
24 h 37.6 33.3 76 90 
36 h 60.4 38.1 69.3 75.8 
PMA+ionomycin 
0 h 6.24 3.44 6.97 2.6 
24 h 9.2 16 68.5 73 
36 h 33.9 53.3 97.6 96.5 
(A) Cell lines. Cell lines were tested by indirect immunofluorescence analysis in a FACScan with rat mAbs 90.60.3, 7D4 (anti-IL- 
2R~), TMI31 (anti-IL-2R[~), or TUGm2 (anti-IL-2RT). All cloned cell lines exhibit uniform staining. Relative fluorescence intensity is 
indicated as high, intermediate, low, or negative. See Fig. 4 for experimental details. (B) Cultured splenic T-cells. Freshly isolated T- 
cells (purity > 90%) were analyzed by FACScan before or after mitogenic stimulation. Two color staining was performed with mAbs 
90.60.3 or 7D4; and directly labeled anti-CD4 or anti-CD8. Data shown is from the CBA/Ca strain, and was reproducible with cells 
isolated from Balb/c and C57BL6 strains (data not shown). Data shown are percent of cells stained. 
mAb 90.60.3 does not bind the IL-2Rt~ transfected 
EL4 cells. Thus, mAb 90.60.3 does not bind IL-2Rt~ 
subunits, and expression of IL-2Rtx does not inevi- 
tably result in co-expression of the 90.60.3 phospho- 
lipid (Table 2A). 
Likewise, expression of  IL-2RI3 and IL -2Ry sub- 
units do not result in expression of the 90.60.3 phos- 
pholipid (Table 2A). mAb 90.60.3 binds to BAF-3 
cells which are negative for IL-2R[5 receptors. COS 
fibroblasts transfected with mouse IL-2Rt~ or IL-2RI3 
cDNAs showed no reactivity with mAb 90.60.3, 
while they did bind the appropriate ant i - IL -2R~ 
and anti-IL-2R]5 Abs (data not shown). In addition, 
mAb 90.60.3 did not bind the IL-9-dependent T-cell 
line TS1 (Table 2A) which expresses high levels of 
IL -2Ry subunits [10]. 
These data strongly indicate that the antigen rec- 
ognized by mAb 90.60.3 is not the IL-2Rt~, IL-2RI3, 
or IL-2R'~ subunits. Furthermore, mAb 90.60.3 did 
not bind some lymphoid cell lines including 2B4 T- 
cell hybridoma, SP2/0 B-cell myeloma, T -ALL  hu- 
man leukemia, Jurkat human T-cells, THP  1 promon-  
ocytic cells, and CD34 ÷ cells TF1 and K61a cells; or 
a variety of non- lymphoid cells of  fibroblastoid, epi- 
thelial, and neuronal origin (data not shown). 
3.5. Expression of  the 90.60.3 phospholipid in the 
outer leaflet of  normal T-cells 
We next analyzed 90.60.3 expression in freshly iso- 
lated T-cells f rom BALB/c, C57BL/6 and CBA/Ca 
mice (Table 2B). Surface expression was detected 
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rose to 30-60% of all T-cells after 36 h of in vitro 
mitogenic stimulation with either Concanavalin A, 
anti-CD3 (mAb 500A2), or PMA and ionomycin. 
Both the CD4 + and CD8 + subsets were induced to 
express 90.60.3 phospholipid upon activation. Fur- 
thermore, the 90.60.3 phospholipid was also detected 
on a subpopulation f CD4- CD8- cells from spleen 
and lymph nodes 24-36 h after activation with PMA 
and ionomycin (data not shown). We have not tried 
to identify these cells, which are likely to include B- 
cells. 
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Fig. 4. Proximity of 90.60.3 phospholipid and the IL-2 binding 
domain of IL-2Rc~. Various mAbs were tested for cross-inhibi- 
tion of cell surface binding. Saturating concentrations of each 
mAb were pre-determined ( ata not shown) and used. (A) In- 
hibition of anti-IL-2Ret mAb 5A2 binding by mAb 90.60.3. 
Anti-IL-2R[~ and IL-2R? mAbs had no effect in mAb 5A2 
binding. (B) Inhibition of mAb 90.60.3 by anti-IL-2Ra mAb 
5A2. Anti-IL-2RI3 and IL-2Ry mAbs had no effect in mAb 
90.60.3 binding, (C) mAb 90.60.3 inhibited the binding of anti- 
IL-2R~x mAb AMT-13 by more than 50% (solid line, filled), 
while anti-IL-2Ra mAbs 7D4 or 2E4 (dashed and solid lines, 
empty) had no effect in mAb AMT-13 binding. (D) Saturating 
amounts of mAb M1.42.6 to class I MHC, 50 ~tg rat IgG, or 
20% fetal calf serum used as controls, none of which affected 
subsequent binding of AMT-13 mAb by > 5%. For a complete 
summary see Table 3. 
3.6. Association of 90.60.3 phospholipids and IL-2Rot 
subunits 
A potential association of IL-2R subunits with the 
90.60.3 phospholipid was studied to evaluate whether 
the functional synergy of mAb 90.60.3 and IL-2 was 
germane to IL-2R signaling. 
Thus, we studied whether mAb 90.60.3, mAb 5A2 
(anti-IL-2Ra), mAb TM~I (anti-IL-2R~), and 
TUGm2 (anti-IL-2R?) would reciprocally affect 
each other's binding to the cell surface (Fig. 4A,B). 
This study was done by FACScan analysis, measur- 
ing heterologous blocking of one antibody upon the 
binding of a different antibody which was directly 
fluorescinated or biotinylated. Control 'self competi- 
tion' gauged homologous blocking. 
The binding of labeled mAb 5A2 was progressively 
reduced by increasing concentrations of mAb 90.60.3 
(Fig. 4A). In control experiments, the binding of la- 
beled mAb 5A2 was efficiently cold-competed by un- 
labeled 5A2; but mAbs TM~I and TUGm2 had no 
effect. In the reciprocal assay, binding of labeled 
mAb 90.60.3 was reduced by increasing concentra- 
tions of mAb 5A2 (Fig. 4B). In control assays, the 
binding of labeled mAb 90.60.3 was efficiently cold- 
competed by unlabeled mAb 90.60.3; but mAbs 
TM[31 and TUGm2 had no effect. 
These data suggest an association of the 90.60.3 
phospholipid with IL-2Ro~ subunits; and suggests 
the absence of an association of the 90.60.3 phospho- 
lipid with IL-2R~ and IL-2R 7 subunits. 
on a small percentage (5-10%) of T-cells freshly iso- 
lated from thymus, from spleen, or from lymph no- 
des. Surface expression of the 90.60.3 phospholipid 
3.7. The 90.60.3 phospholipid is linked to the 1L-2 
binding domain of 1L-2Rot 
Given the putative link of the 90.60.3 phospholipid 
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and IL-2Rtx, we studied this association in more de- 
tail. For  that purpose, several antibodies that recog- 
nize IL-2Ro~ subunits are available. Previous epitope 
mapping of anti-IL-2Rt~ antibodies have defined 
three clusters [35,36]. In cluster I, mAbs AMT-13, 
5A2, and 3C7 bind to epitopes overlapping with 
the IL-2 binding site on IL-2Ro~. Their binding is 
reciprocally inhibited by binding of  IL-2, or by any 
of these mAbs. In cluster II, epitopes recognized by 
mAbs 7D4 and 2E4 are distinct from the binding 
site of IL-2 on IL-2Rtx. In cluster III, mAb PC61 
binding reduces IL-2 binding to IL-2Rtx by induc- 
ing conformational changes rather than by steric 
hindrance. These published data were reproduced 
as internal controls in assays summarized in 
Table 3. 
FACScan assays tested whether mAb 90.60.3 or 
mAbs directed to each of the IL-2Ro~ clusters recip- 
rocally inhibit each other (Fig. 4C,D). Binding of  
mAb 90.60.3 led to a greater than 50% reduction 
of  binding of mAb AMT-13 to HT-2 cells (Fig. 
4C). The specificity of  inhibition is shown by the 
inability of  mAb 90.60.3 to affect binding of  mAbs 
7D4 or 2E4 (Fig. 4C), nor did 2E4 or 7D4 mAbs 
inhibit binding of  mAb 90.60.3 (data not shown, see 
Table 3). Further controls included saturating 
amounts of  mAb M1.42.6 against MHC class I, 
50 gg/ml rat Ig, or 20% fetal calf serum, none of 
which affected subsequent binding of  any antibody 
by > 5% (Fig. 4D). 
A summary of results are presented in Table 3, 
and demonstrate that binding of mAb 90.60.3 leads 
to a significant inhibition of subsequent binding of 
all anti-IL-2Rtx mAbs which interact with the IL-2 
binding domain of  this subunit (cluster 1). In the 
reciprocal experiment, binding of  mAbs against clus- 
ter 1 significantly inhibited binding of mAb 90.60.3. 
In control assays, none of the mAbs against different 
clusters of  IL-2Rot or other mAbs reciprocally af- 
fected mAb 90.60.3 binding. 
The effect of prior binding of IL-2 on the binding 
of  mAb 90.60.3 or antibodies to IL-2R was also 
tested by indirect immunofluorescence. IL-2 did not 
reduce binding of mAb 90.60.3 (Table 3). Similarly, 
previous binding of 90.60.3 mAb had no effect on 
binding of 125I[IL-2] to high or low affinity receptors 
on HT-2 cells as measured in Scatchard plot analysis 
(data not shown). In contrast, in control experiments 
IL-2 blocked binding of  all antibodies of  cluster I 
(AMT-13, 5A2, 3C7), but not of those of cluster II 
(7D4, 2E4) (Table 3) as previously reported. We in- 
terpret these results to mean that the 90.60.3 phos- 
pholipid is in contact with IL-2Ro~ in a specific and 
invariant orientation towards the face of IL-2Rct 
which binds IL-2, and away from the domain(s) rel- 
evant for binding other antML-2R mAbs. 
4. Discussion 
We have characterized biochemically and function- 
ally an activation marker related to POPC phospho- 
lipids, present on the outer leaflet of  the cell mem- 
brane. In cell cultures, binding of the phospholipid 
with 90.60.3 mAb results in enhanced signal trans- 
duction via IL-2R. 
Table 3 
Specific inhibition of anti-IL-2Rc~ cluster 1 mAb binding by mAb 90.60.3 
Cold competitor Labeled ligand 
FITC-7D4 Biotin-3C7 Biotin-AMT13 Biotin-5A2 Biotin-M 1.42 125I[IL-2] Biotin-90.60 
7D4 (anti-IL-2R~) ++++ - - NT - - - 
3C7 (anti-IL-2Rct) - ++++ +++ NT - +++ +++ 
AMT13 (anti-IL-2R~) - +++ ++++ +++ - ++ +++ 
5A2 (anti-IL-2Re0 NT NT +++ ++++ - NT +++ 
M1.42 (anti-MHC) . . . .  ++++ - - 
IL-2 - +++ +++ NT - ++++ - 
90.60.3 - +++ +++ ++ - - ++++ 
Summary of the results presented in Fig. 3. Blocking/inhibition studies were performed as described in Section 2. All ligands were bio- 
tinylated, with the exception of 7D4 (which was directly fluorescinated), and radiolabeled L25I[IL-2]. After washing, the biotinylated 
antibodies were detected with avidin-FITC. 125I[IL-2] cpm were counted. Data represents inhibition of maximal binding in arbitrary 
units: ++++, > 50% inhibition; +++, 35-50% inhibition; ++, 15-35% inhibition; - ,  < 5% inhibition; NT, not tested. 
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4.1. The 90.60.3 antigen 
The minimal 90.60.3 antigen is a POPC-like phos- 
pholipid comprised of: (1) choline; (2) a diester link- 
age; and (3) two lipid chains of 12-18 carbons in 
length containing at least one C=C double bond. 
Choline and the diester linkage could be exposed 
on the outer leaflet of the plasma membrane as com- 
ponents of several molecules. However, it is unclear 
how lipid chains with C = C double bonds could be 
exposed to the hydrophilic environment and made 
available for binding by mAb 90.60.3. It is also in- 
triguing that while all cells have POPC on the plasma 
membrane, mostly T-lymphoid cells are bound by 
mAb 90.60.3. 
One possibility that may account for mAb 90.60.3 
binding is that some tails containing a C = C double 
bond bend at angles of ~ 130 ° within the lipid bi- 
layer. Bending alters the chemistry and the state of 
the lipid-non-lipid monolayer interface [37 39]. If 
the 90.60.3 antigen is POPC, perhaps activated T- 
cells have the ability to flip lipids or to expose the 
lipid C = C double bonds more efficiently than other 
ceils. However, it is also possible that the 90.60.3 
antigen is distinct from POPC and this issue awaits 
resolution. It is noteworthy that antibodies against 
lipids are rare, but there are mAbs that discriminate 
between POPC and PEA [40,41]. 
4.2. Expression of the 90.60.3 phospholipid 
The 90.60.3 phospholipid is a marker expressed on 
the cell surface after T-cell activation. It is induced 
on mouse T-cells as early as 18 h post-activation i
vitro and maximally by 36 h. The increase in 90.60.3 
phospholipid expression is distinct, but parallel to 
that of IL-2Ra subunits and transferrin receptors 
(data not shown). Interestingly, the kinetics of 
90.60.3 phospholipid expression also parallels IL-2 
responsiveness by activated T-cells. 
The 90.60.3 marker is not the IL-2Ra[37 polypep- 
tides. Since IL-2 does not affect the binding of mAb 
90.60.3 and mAb 90.60.3 does not affect the affinity 
of IL-2, it is unlikely that the 90.60.3 antigen repre- 
sents a new IL-2 binding subunit. Furthermore, cells 
expressing 90.60.3 phospholipid o not bind IL-2 in 
the absence of IL-2R subunits, and not all IL-2 re- 
sponsive cells express 90.60.3 phospholipids. 
4.3. Physical association of 90.60.3 and IL-2Ra 
subunits 
Cross-inhibition of binding between antibodies to 
distinct, but membrane-associated structures is a 
common phenomenon, and the degree of this inhib- 
ition has been used to study the spatial relationships 
between different subunits of multiple subunit recep- 
tors [42~4]. Based on cross-inhibition studies, we 
have observed that the 90.60.3 phospholipid can as- 
sociate with a specific domain of IL-2Ra which is 
involved in IL-2 binding. 
We have assumed that the ability of 90.60.3 mAb 
to block some anti-IL-2Ra mAbs is based on steric 
hindrance, a possibility supported by the fact that 
IL-2 and mAb 90.60.3 do not block each other's 
binding. However, we have been unable to consis- 
tently co-immunoprecipitate 90.60.3 phospholipids 
and IL-2R subunits (data not shown). This may be 
due to technical difficulties or because IL-2R sub- 
unit-phospholipid association is not stable to deter- 
gent lysis. 
4.4. Functional association of 90.60.3 and IL-2R 
Likely the phospholipid recognized by mAb 
90.60.3 is not involved in IL-2 binding but in IL-2 
function. The 90.60.3 antigen seems to associate with 
cell surface IL-2Ra subunits and synergizes function- 
ally with low levels of IL-2 to increase IL-2-depend- 
ent survival and proliferation. 
Cell culture with mAb 90.60.3 does not allow for 
long-term responses (> 3 days) in the complete ab- 
sence of IL-2. Thus, the mAb does not act as a cy- 
tokine or growth factor. Rather, the mAb potentiates 
the biological activity of IL-2. While mAb 90.60.3 
did not affect the affinity of IL-2R for IL-2, we 
have not yet compared IL-2 affinities in 90.60.3 pos- 
itive versus 90.60.3 negative cells. It would be inter- 
esting to do so because there is a precedent wherein 
the affinity of epidermal growth factor (EGF) was 
affected by lipid composition. The introduction of 
cholesterol or phosphatidylinositol lipids (but not 
phosphatidylserine or phosphatidic acid) into 
DOPC vesicles resulted in a 6-18-fold increase in 
the affinity of the EGF receptor for EGF [54]. 
It is also possible that the short-term responses by 
HT-2 and CTL-L cells in the absence of IL-2 simply 
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reflects a carry over of IL-2 which remains bound to 
the cells even after washing. Thus, an alternative 
possibility is that the apoptotic mechanism induced 
on HT-2 and CTL-L cells after IL-2 withdrawal may 
be delayed by mAb 90.60.3, but IL-2 is absolutely 
required for long-term growth. Indeed, lipid peroxi- 
dation is a marker of apoptosis, and perhaps mAb 
90.60.3 binds to or sequesters peroxidated phospho- 
lipids. 
4.5. 90.60.3 Phospholipid cell surface density 
Taken together, our observations uggest that 
mAb 90.60.3 synergizes with IL-2 to affords trophic 
signals. Synergy of IL-2 and mAb 90.60.3 in culture 
required high surface density of 90.60.3 phospho- 
lipids, which is directly related to logarithmic cell 
growth. Nutrient depleted or cell cycle arrested cells 
express > 500-fold reduced 90.60.3 density (data not 
shown). Consistent, mAb 90.60.3+IL-2 synergy did 
not occur when surface expression of 90.60.3 phos- 
pholipids were low after partial starvation of the cells 
(data not shown). Perhaps optimal growth condi- 
tions are required for high expression of the 90.60.3 
phospholipid and consequent function. 
The ability of mAb 90.60.3 to potentiate IL-2 but 
not IL-4 remains to be studied further. It is intrigu- 
ing that IL-4 responses are not potentiated, even in 
cells such as HT-2 or CTL-L which possess the ma- 
chinery required to respond. Experiments using the 
IL-4 dependent (and IL-2 responsive) CT4-S cell line, 
derived from CTL-L cells [31], demonstrated that the 
pathways for signaling in response to mAb 90.60.3 
binding are intact in the presence of IL-2, but fail to 
function in response to IL-4. The only phenotypic 
differences observed on the CT4-S line when com- 
pared to the parental CTL-L line were: (1) reduced 
levels of IL-2Ra; (2) reduced levels of the 90.60.3 
phospholipid; and (3) they are more adherent o 
plastic. 
These three differences may account for lack of 
synergy in CT4-S cells, because perhaps IL-2R~ sub- 
units or IL-2 itself are required for high density of 
surface expression of the 90.60.3 phospholipid (in 
analogy to IL-2 upregulation of IL-2Ra subunits 
[45]). However, our data argue against his possibil- 
ity because EL4 cells expressing high affinity IL-2R 
after transfection with IL-2Ra cDNA do not express 
the 90.60.3 phospholipid, even after culture with 
IL-2. 
Biological assays also indicated that co-culture 
with mAb 90.60.3 causes a significant but poor syn- 
ergy with IL-3, and failed to synergize with IL-12 
(data not shown). This was surprising, as both IL-3 
and IL-12 are known to potentiate IL-2 responses in 
non-T-cells. We have not tested whether mAb 
90.60.3 synergizes with IL-7 as would be expected 
for a IL-2Ry subunit mediated signal. 
4.6. Potential role of lipids in IL-2 signals 
The functional association of lipids and IL-2 or 
IL-2 receptors has been suggested [46-49]. Similarly, 
there are other mAbs not directed to IL-2R that 
affect IL-2 responses [50,51]. However these mole- 
cules affect responses negatively as opposed to 
mAb 90.60.3 which affects IL-2 responses positively. 
The lipids sphingomyelin and ceramide, and lipid 
peroxidation play a role in apoptotic cell death 
[52,53]. Thus, an mAb against a lipid may protect 
cells from apoptosis, as does mAb 90.60.3 in culture. 
While the biological effect of mAb 90.60.3 may be 
attributed to selective inhibition of lipid peroxidation 
or to inhibition of sphingomyelin metabolism; the 
binding characteristics of mAb 90.60.3 and a selective 
blockade of anti-IL-2Ra antibodies suggest other- 
wise. 
The 90.60.3 phospholipid seems to play a role in 
specific IL-2 signaling, but its mechanism of action 
remains unknown. We are interested in identifying 
the signal transduction mechanism and in exploring 
whether protein phosphorylation is involved. Taken 
together, the data suggest hat the 90.60.3 phospho- 
lipid is a novel structure distinct from IL-2 receptors, 
but capable of associating with this (and perhaps 
other) lymphokine receptors. 
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